Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) have been assigned an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $21.50.

TARA has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, January 22nd. Piper Sandler initiated coverage on Protara Therapeutics in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $24.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Tuesday, February 10th. Finally, JPMorgan Chase & Co. initiated coverage on Protara Therapeutics in a research report on Wednesday. They set an “overweight” rating and a $27.00 target price for the company.

Institutional Trading of Protara Therapeutics

Several large investors have recently made changes to their positions in TARA. Janus Henderson Group PLC grew its position in shares of Protara Therapeutics by 21.5% in the 4th quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock valued at $27,379,000 after buying an additional 910,285 shares during the last quarter. Velan Capital Investment Management LP boosted its holdings in Protara Therapeutics by 32.5% in the fourth quarter. Velan Capital Investment Management LP now owns 2,834,652 shares of the company’s stock valued at $15,109,000 after acquiring an additional 695,652 shares during the last quarter. Integral Health Asset Management LLC boosted its holdings in Protara Therapeutics by 60.7% in the fourth quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock valued at $11,992,000 after acquiring an additional 850,000 shares during the last quarter. Vanguard Group Inc. increased its position in Protara Therapeutics by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,904,156 shares of the company’s stock valued at $8,283,000 after purchasing an additional 102,176 shares during the period. Finally, Acorn Capital Advisors LLC lifted its position in shares of Protara Therapeutics by 36.9% in the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company’s stock worth $5,309,000 after purchasing an additional 472,315 shares during the period. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Stock Up 1.4%

TARA opened at $5.90 on Friday. Protara Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.82. The business has a 50 day moving average of $6.08 and a 200-day moving average of $5.28. The stock has a market cap of $304.62 million, a price-to-earnings ratio of -4.13 and a beta of 1.40.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.